We are live on ! Find out more
AVEO

AVEO Pharmaceuticals, Inc.
AVEO

Delisted

AVEO was delisted on the 19th of January, 2023.

Back to rankings

0 hedge funds and large institutions have $0 invested in AVEO Pharmaceuticals, Inc. in 2023 Q1 according to their latest regulatory filings, with 0 funds opening new positions, 0 increasing their positions, 0 reducing their positions, and 110 closing their positions.

New
Increased
Maintained
Reduced
Closed

100% less funds holding

Funds holding: 110 → 0 (-110)

100% less funds holding in top 10

Funds holding in top 10: 1 → 0 (-1)

100% less capital invested

Capital invested by funds: $368M → $0 (-$368M)

100% less first-time investments, than exits

New positions opened: 0 | Existing positions closed: 110

Holders
–
Holders Change
-110
Holders Change %
-100%
% of All Funds
–
Holding in Top 10
–
Holding in Top 10 Change
-1
Holding in Top 10 Change %
-100%
% of All Funds
–
New
–
Increased
–
Reduced
–
Closed
110
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

No buyers this quarter

Top Sellers

Rank Fund Capital Flow
1
Vanguard Group
Vanguard Group
Pennsylvania
-$22.6M
2
NAM
Nexpoint Asset Management
Texas
-$21.9M
3
Balyasny Asset Management
Balyasny Asset Management
Illinois
-$21.6M
4
AllianceBernstein
AllianceBernstein
Tennessee
-$20.1M
5
Man Group
Man Group
United Kingdom
-$19.4M
Name Holding Trade Value Shares
Change 		Change in
Stake
TI
51
Trexquant Investment
Connecticut
– -$1.1M -73,900 Closed
BCM
52
BCK Capital Management
Connecticut
– -$1.02M -68,000 Closed
Squarepoint
53
Squarepoint
New York
– -$936K -62,618 Closed
Northern Trust
54
Northern Trust
Illinois
– -$930K -62,186 Closed
GCL
55
Glazer Capital LLC
New York
– -$928K -62,066 Closed
HF
56
HRT Financial
New York
– -$866K -57,975 Closed
Bank of New York Mellon
57
Bank of New York Mellon
New York
– -$803K -53,733 Closed
BCM
58
Bridgeway Capital Management
Texas
– -$792K -53,000 Closed
Millennium Management
59
Millennium Management
New York
– -$737K -49,299 Closed
Mariner
60
Mariner
Kansas
– -$713K -47,691 Closed
LCM
61
Landscape Capital Management
New Jersey
– -$664K -44,436 Closed
EWM
62
Evercore Wealth Management
New York
– -$626K -41,841 Closed
Ameriprise
63
Ameriprise
Minnesota
– -$608K -40,705 Closed
Voloridge Investment Management
64
Voloridge Investment Management
Florida
– -$606K -40,557 Closed
MOS
65
MGO One Seven
Ohio
– -$598K -40,000 Closed
SC
66
Sagefield Capital
Texas
– -$598K -40,000 Closed
Barclays
67
Barclays
United Kingdom
– -$515K -34,444 Closed
Group One Trading
68
Group One Trading
Illinois
– -$512K -34,258 Closed
State of Wisconsin Investment Board
69
State of Wisconsin Investment Board
Wisconsin
– -$466K -31,186 Closed
DC
70
Diametric Capital
Massachusetts
– -$447K -29,909 Closed
Walleye Capital
71
Walleye Capital
New York
– -$427K -28,589 Closed
PCM
72
PenderFund Capital Management
British Columbia, Canada
– -$563K -27,800 Closed
California State Teachers Retirement System (CalSTRS)
73
California State Teachers Retirement System (CalSTRS)
California
– -$404K -27,054 Closed
CCM
74
Chicago Capital Management
Illinois
– -$374K -25,000 Closed
Wellington Management Group
75
Wellington Management Group
Massachusetts
– -$344K -22,988 Closed
1 2
3
4 5

AVEO Hedge Fund Activity: Q1 2023 in Review

0 of the 6,275 institutional investors tracked by Wall St. Rank reported a position in AVEO Pharmaceuticals, Inc. (AVEO) for Q1 2023, worth a combined $0 — down 100% from $368M a quarter earlier.

Sellers outnumbered buyers: 110 funds closed out of AVEO and 0 opened new positions — a net loss of 110 holders — while 0 trimmed existing stakes and 0 added.

The largest seller was Vanguard Group, exiting entirely with an estimated $22.6M sold.

  • 0 institutional investors held AVEO Pharmaceuticals, Inc. (AVEO) as of Q1 2023, down from 110 in Q4 2022.
  • Funds reported $0 of AVEO Pharmaceuticals, Inc. stock for Q1 2023, down 100% quarter-over-quarter.
  • 0 funds opened new AVEO Pharmaceuticals, Inc. positions in Q1 2023 and 110 closed out, a net change of -110 holders.
  • The largest AVEO Pharmaceuticals, Inc. seller in Q1 2023 was Vanguard Group, an estimated $22.6M sold.

Based on aggregated 13F filings for Q1 2023.